Mind Medicine (MindMed) (MNMD) versus The Competition Critical Analysis

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) is one of 49 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Mind Medicine (MindMed) to similar businesses based on the strength of its risk, profitability, earnings, dividends, institutional ownership, valuation and analyst recommendations.

Earnings and Valuation

This table compares Mind Medicine (MindMed) and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mind Medicine (MindMed) N/A -$93.04 million -3.79
Mind Medicine (MindMed) Competitors $238.90 million -$88.34 million -7.81

Mind Medicine (MindMed)’s rivals have higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Mind Medicine (MindMed) and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed) 0 0 2 0 3.00
Mind Medicine (MindMed) Competitors 265 672 671 26 2.28

Mind Medicine (MindMed) currently has a consensus target price of 8.00, indicating a potential upside of 817.54%. As a group, “Medicinals & botanicals” companies have a potential upside of 105.88%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher possible upside, equities analysts clearly believe Mind Medicine (MindMed) is more favorable than its rivals.

Profitability

This table compares Mind Medicine (MindMed) and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed) N/A -55.27% -51.10%
Mind Medicine (MindMed) Competitors -179.06% -256.89% -16.07%

Institutional & Insider Ownership

10.8% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 19.0% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 26.5% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About Mind Medicine (MindMed) (Get Rating)

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.